02 March 2021
: Case report 
Serratia marcescens Infection-Associated Loss of Vision: A Case Report in a Patient with a History of Intravenous Drug Use
Rare disease
Shirisha Pasula1ABCDEFG*, Vichar Trivedi2BEF, Elvisa Loshe3BD, Pranatharthi Chandrasekar2DEGDOI: 10.12659/AJCR.929116
Am J Case Rep 2021; 22:e929116
Table 2. Antimicrobial susceptibilities of Serratia marcescens.
| Antimicrobial | MIC | ET1 susceptibility | Interpretation | Et1 interpretation |
|---|---|---|---|---|
| Amp/Sulbactam | >16/8 | Resistant | ||
| Ampicillin | >16 | Resistant | ||
| Aztreonam | ≤1 | Susceptible | ||
| Cefazolin | >32 | Resistant | ||
| Cefepime | ≤0.5 | Susceptible | ||
| Cefoxitin | >16 | Resistant | ||
| Ceftazidime | ≤0.5 | Susceptible | ||
| Ceftriaxone | ≤0.5 | Susceptible | ||
| Ciprofloxacin | 0.12 | Susceptible | ||
| Ertapenem | ≤0.125 | Susceptible | ||
| Gentamicin | 2 | Susceptible | ||
| Imipenem | 1 | Susceptible | ||
| Meropenem | ≤0.125 | Susceptible | ||
| Piperacillin/Tazobactam | ≤4/4 | Susceptible | ||
| Tobramycin | 2 | Susceptible | ||
| MIC – minimum inhibitory concentration; ET – epsilometer test. | ||||